Prevention of acute venous stent-induced thrombosis using inhibition of fxii

Khanh P. Nguyen, Michael Wallisch, Jennifer Johnson, András Gruber, Monica T. Hinds

    Research output: Chapter in Book/Report/Conference proceedingConference contribution

    Abstract

    Acute proximal lower extremity deep vein thrombosis (DVT) affects 1-2 per 1000 patients annually and confers significant acute and chronic morbidity and mortality. Pulmonary embolism (PE) and post-thrombotic syndrome (PTS) remain prevalent and hard-to-manage complications after DVT despite medical therapy. Treatment and recanalization of symptomatic, iliofemoral venous stenosis or obstruction, the long-term sequelae of DVT and DVT-associated PTS, by angioplasty and stenting is indicated in select ambulatory patients. While venous stenting can improve and restore blood flow in some cases, patency rates are poor with 1-year patency rates of 70% and significantly lower 5-year patency rates. After stenting, medical management of DVT requires either anti-platelet therapy and/or anticoagulation, which improves primary patency rates but carries a significant, 2-4% annual risk of major bleeding. Modern anticoagulation therapy including vitamin K antagonists, direct thrombin inhibitors and Factor X inhibitors have significant bleeding risks due to the impairment of hemostasis. As many patients require long-term medical therapy, development of a novel anticoagulant with a lower risk profile is critical. Since coagulation factor XII (FXII) supports contact activation of blood but has no known contribution to hemostasis, we sought to determine the thrombogenic role of FXII in an acute ex vivo venous stent model utilizing a FXII-neutralizing monoclonal antibody, 5C12.

    Original languageEnglish (US)
    Title of host publicationSociety for Biomaterials Annual Meeting and Exposition 2019
    Subtitle of host publicationThe Pinnacle of Biomaterials Innovation and Excellence - Transactions of the 42nd Annual Meeting
    PublisherSociety for Biomaterials
    Pages20
    Number of pages1
    ISBN (Electronic)9781510883901
    StatePublished - 2019
    Event42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence - Seattle, United States
    Duration: Apr 3 2019Apr 6 2019

    Publication series

    NameTransactions of the Annual Meeting of the Society for Biomaterials and the Annual International Biomaterials Symposium
    Volume40
    ISSN (Print)1526-7547

    Conference

    Conference42nd Society for Biomaterials Annual Meeting and Exposition 2019: The Pinnacle of Biomaterials Innovation and Excellence
    Country/TerritoryUnited States
    CitySeattle
    Period4/3/194/6/19

    ASJC Scopus subject areas

    • Biochemistry
    • Biophysics
    • Biotechnology
    • Biomaterials
    • Materials Chemistry

    Fingerprint

    Dive into the research topics of 'Prevention of acute venous stent-induced thrombosis using inhibition of fxii'. Together they form a unique fingerprint.

    Cite this